Literature DB >> 7673399

Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome.

J Holte1, T Bergh, C Berne, L Wide, H Lithell.   

Abstract

The impact of weight reduction on metabolic, endocrine, and anthropometric variables was studied in 13 obese, insulin-resistant women with the polycystic ovary syndrome (PCOS). Insulin sensitivity (euglycemic insulin clamp), insulin secretion and glucose tolerance (iv glucose tolerance test), basal sex steroid hormones, gonadotropins and free fatty acids (FFA), skin folds and waist hip ratio (WHR) were evaluated before (PCO-BD) and after (PCO-AD) diet-induced weight reduction to a weight stable level [mean (SD) diet duration 14.9 (6.2) months]. Mean weight loss was 12.4 kg (4.7; P < 0.0001), equalling a reduction from a body mass index (BMI) of 32.2 (3.7) kg/m2 to 27.6 (3.7; P < 0.0001) kg/m2. The results were compared with those of two groups of weight stable (no diet) women, 21 with PCOS (PCO-ND) and 23 normal control subjects (C), who were matched to the BMI the diet group reached after weight loss. Insulin sensitivity index (M/I) improved on average 132% (P < 0.001) and plasma FFA by 32% (P < 0.01), serum sex hormone binding globulin levels increased by 35% (P < 0.01), and the sum of truncal-abdominal skin-folds (subscapular, umbilical, and suprailiacal) were reduced by 28% (P < 0.0001), whereas the early insulin response to iv glucose, the levels of gonadotropins and androstenedione, and the femoral sc fat did not change significantly with weight loss. M/I, levels of SHBG and FFA and truncal-abdominal fat reached levels similar to the controls, whereas PCO-ND had lower M/I (P < 0.01) and SHBG levels (P < 0.0001), greater concentrations of FFA (P < 0.01) and truncal-abdominal fat (P < 0.05) than C. Among women with normal glucose tolerance, the insulin increment was higher in both PCO-AD (P < 0.05) and PCO-ND (P < 0.01) than in C. There was a strong correlation between M/I and sum of truncal-abdominal skinfolds in all groups (PCO-BD: r = 0.82; P < 0.001, PCO-AD: r = 0.68; P < 0.05, PCO-ND: r = 0.81; P < 0.0001, C: r = 0.44; P < 0.05). The variation in M/I in PCO-AD and PCO-ND (pooled) was best explained by FFA and truncal-adbominal fat (model R2 = 0.67). In conclusion, insulin resistance in obese women with PCOS was reduced by weight loss to similar levels as BMI-matched control subjects, suggesting that insulin resistance in PCOS is not a feature of PCOS per se.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7673399     DOI: 10.1210/jcem.80.9.7673399

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  56 in total

1.  Euglena gracilis deoxyribonucleic acid polymerases: subcellular locations and variations during the cell cycle.

Authors:  A G McLennan; H M Keir
Journal:  Biochem Soc Trans       Date:  1975       Impact factor: 5.407

Review 2.  Genetics of ovarian disorders: polycystic ovary syndrome.

Authors:  Stephen Franks; Mark McCarthy
Journal:  Rev Endocr Metab Disord       Date:  2004-03       Impact factor: 6.514

3.  Interventional studies for polycystic ovarian syndrome in children and adolescents.

Authors:  Patricia Myriam Vuguin
Journal:  Ped Health       Date:  2010-02

Review 4.  How actual is the dietary treatment in overweighting patients with polycystic ovary syndrome?

Authors:  C Cortet-Rudelli; D Dewailly
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 5.  New routes in the polycystic ovary syndrome labyrinth: a way out?

Authors:  P Moghetti; R Castello
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

6.  Metabolic, behavioral, and reproductive effects of vertical sleeve gastrectomy in an obese rat model of polycystic ovary syndrome.

Authors:  Ilana B Ressler; Bernadette E Grayson; Randy J Seeley
Journal:  Obes Surg       Date:  2014-06       Impact factor: 4.129

7.  Genetics of polycystic ovary syndrome.

Authors:  N Prapas; A Karkanaki; I Prapas; I Kalogiannidis; I Katsikis; D Panidis
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

Review 8.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

9.  The Effect of Flaxseed Supplementation on Hormonal Levels Associated with Polycystic Ovarian Syndrome: A Case Study.

Authors:  Debra A Nowak; Denise C Snyder; Ann J Brown; Wendy Demark-Wahnefried
Journal:  Curr Top Nutraceutical Res       Date:  2007       Impact factor: 0.416

10.  Current trends in the treatment of polycystic ovary syndrome with desire for children.

Authors:  Margalida E Sastre; Maria O Prat; Miguel Angel Checa; Ramon C Carreras
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.